Literature DB >> 34304253

Immune checkpoint inhibitors and allogeneic transplant in lymphoid malignancies: a deceptive friend story.

Mohammed Al Farttoosi1, Jean El Cheikh2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34304253     DOI: 10.1038/s41409-021-01396-6

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  12 in total

1.  Non-Myeloablative Allogeneic Transplantation with Post-Transplant Cyclophosphamide after Immune Checkpoint Inhibition for Classic Hodgkin Lymphoma: A Retrospective Cohort Study.

Authors:  Suman Paul; Marianna Zahurak; Leo Luznik; Richard F Ambinder; Ephraim J Fuchs; Javier Bolaños-Meade; Nina Wagner-Johnston; Lode J Swinnen; Laura Schoch; Ravi Varadhan; Richard J Jones; Douglas E Gladstone
Journal:  Biol Blood Marrow Transplant       Date:  2020-06-24       Impact factor: 5.742

2.  Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.

Authors:  Philippe Armand; Margaret A Shipp; Vincent Ribrag; Jean-Marie Michot; Pier Luigi Zinzani; John Kuruvilla; Ellen S Snyder; Alejandro D Ricart; Arun Balakumaran; Shelonitda Rose; Craig H Moskowitz
Journal:  J Clin Oncol       Date:  2016-11-01       Impact factor: 44.544

3.  Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide.

Authors:  Laura K Schoch; Kenneth R Cooke; Nina D Wagner-Johnston; Ivana Gojo; Lode J Swinnen; Philip Imus; Ephraim J Fuchs; Mark Levis; Richard F Ambinder; Richard J Jones; Douglas E Gladstone
Journal:  Blood Adv       Date:  2018-09-11

4.  Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087.

Authors:  Robert Chen; Pier Luigi Zinzani; Hun Ju Lee; Philippe Armand; Nathalie A Johnson; Pauline Brice; John Radford; Vincent Ribrag; Daniel Molin; Theodoros P Vassilakopoulos; Akihiro Tomita; Bastian von Tresckow; Margaret A Shipp; Jianxin Lin; Eunhee Kim; Akash Nahar; Arun Balakumaran; Craig H Moskowitz
Journal:  Blood       Date:  2019-08-13       Impact factor: 22.113

5.  PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.

Authors:  Bradley M Haverkos; Diana Abbott; Mehdi Hamadani; Philippe Armand; Mary E Flowers; Reid Merryman; Manali Kamdar; Abraham Sebastian Kanate; Ayman Saad; Amitkumar Mehta; Siddhartha Ganguly; Timothy S Fenske; Parameswaran Hari; Robert Lowsky; Leslie Andritsos; Madan Jagasia; Asad Bashey; Stacey Brown; Veronika Bachanova; Deborah Stephens; Shin Mineishi; Ryotaro Nakamura; Yi-Bin Chen; Bruce R Blazar; Jonathan Gutman; Steven M Devine
Journal:  Blood       Date:  2017-05-03       Impact factor: 22.113

Review 6.  Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil.

Authors:  Charles Herbaux; Reid Merryman; Steven Devine; Philippe Armand; Roch Houot; Franck Morschhauser; Bradley Haverkos
Journal:  Blood       Date:  2018-05-02       Impact factor: 22.113

Review 7.  Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation.

Authors:  Leo Luznik; Paul V O'Donnell; Ephraim J Fuchs
Journal:  Semin Oncol       Date:  2012-12       Impact factor: 4.929

8.  Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.

Authors:  Philippe Armand; Scott Rodig; Vladimir Melnichenko; Catherine Thieblemont; Kamal Bouabdallah; Gayane Tumyan; Muhit Özcan; Sergio Portino; Laura Fogliatto; Maria D Caballero; Jan Walewski; Zafer Gulbas; Vincent Ribrag; Beth Christian; Guilherme Fleury Perini; Gilles Salles; Jakub Svoboda; Jasmine Zain; Sanjay Patel; Pei-Hsuan Chen; Azra H Ligon; Jing Ouyang; Donna Neuberg; Robert Redd; Arkendu Chatterjee; Arun Balakumaran; Robert Orlowski; Margaret Shipp; Pier Luigi Zinzani
Journal:  J Clin Oncol       Date:  2019-10-14       Impact factor: 44.544

Review 9.  Molecular biology of Hodgkin lymphoma.

Authors:  Marc A Weniger; Ralf Küppers
Journal:  Leukemia       Date:  2021-03-08       Impact factor: 11.528

10.  Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.

Authors:  Anas Younes; Armando Santoro; Margaret Shipp; Pier Luigi Zinzani; John M Timmerman; Stephen Ansell; Philippe Armand; Michelle Fanale; Voravit Ratanatharathorn; John Kuruvilla; Jonathon B Cohen; Graham Collins; Kerry J Savage; Marek Trneny; Kazunobu Kato; Benedetto Farsaci; Susan M Parker; Scott Rodig; Margaretha G M Roemer; Azra H Ligon; Andreas Engert
Journal:  Lancet Oncol       Date:  2016-07-20       Impact factor: 41.316

View more
  1 in total

Review 1.  The Emerging Role of CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma.

Authors:  Jeremy A Meier; Barbara Savoldo; Natalie S Grover
Journal:  J Pers Med       Date:  2022-02-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.